Once again, Fluoguide has managed to turn out a positive top line result in a clinical trial, this time in lung cancer, in which 73% of patients' cancers were illuminated by FG001, with continued a clean safety/tolerability profile and similar pharmacokinetics to that seen in glioma. In our view, this is a promising start to the lung cancer programme and a de-risking event, albeit perhaps not to the same extent as for the earlier glioma and interim head and neck data.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.